F2G
10 known investors
F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective. The company operates an early access program to provide investigational therapies to qualified patients with life-threatening fungal infections who are ineligible for clinical trials or lack suitable alternative treatment options.
Investors · 10
Advent Life SciencesLondon
Aisling CapitalNew York
AMR Action FundBoston
Astellas Venture Management LLCSouth San Francisco · $200K – $5M
Brace PharmaAtlanta
Sofinnova PartnersParis · $540K – $27M
Sunstone CapitalFrederiksberg
ForbionreportedNaarden
Merifin CapitalreportedBrussels · $216K – $3.2M
Novartis Venture FundreportedBasel · $5M – $25M
Funding
SEC filings, press & company announcements$100M disclosed across 1 of 2 rounds · 2022–2024
- $100MraisedSep 2024 · 2 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does F2G do?
- F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective. The company operates an early access program to provide investigational therapies to qualified patients with life-threatening fungal infections who are ineligible for clinical trials or lack suitable alternative treatment options.
- Who are F2G's investors?
- F2G's investors include Advent Life Sciences, Aisling Capital, AMR Action Fund, Astellas Venture Management LLC, Brace Pharma, Sofinnova Partners, Sunstone Capital, Forbion and 2 more.
- How much funding has F2G raised?
- F2G has disclosed $100M raised across 1 of its 2 known rounds.